OOIR: Observatory of International Research

Papers

(The TQCC of SLAS Discovery is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)

Article	Citations
Fast Mek1 Hit Identification with TRIC Technology Correlates Well with Other Biophysical Methods	197
A phenotypic screen for compounds that reverse cAMP-mediated suppression of T cell functions	61
A Phenotypic Approach for the Identification of New Molecules for Targeted Protein Degradation Applications	42
Outline and background for the EU-OS solubility prediction challenge	41
Ex vivo discovery of synergistic drug combinations for hematologic malignancies	38
Publisher's Note	37
Phenotypic Screening Following Transcriptomic Deconvolution to Identify Transcription Factors Mediating Axon Growth Induced by a Kinase Inhibitor	31
High-throughput approaches to uncover synergistic drug combinations in leukemia	30
High content screening miniaturization and single cell imaging of mature human feeder layer-free iPSC-derived neurons	29
Using measures of metabolic flux to align screening and clinical development: Avoiding pitfalls to enable translational studies	28
Saporin, a Polynucleotide–Adenosine Nucleosidase, May Be an Efficacious Therapeutic Agent for SARS-CoV-2 Infection	28
Differential analyte derivatization enables unbiased MALDI-TOF-based high-throughput screening: A proof-of-concept study for the discovery of catechol-o-methyltransferase inhibitors	27
In Vitro Ubiquitination Platform Identifies Methyl Ellipticiniums as Ubiquitin Ligase Inhibitors	27
High throughput assay for compounds that boost BDNF expression in neurons	26
Fluorescent probe for the identification of potent inhibitors of the macrophage infectivity potentiator (Mip) protein of Burkholderia pseudomallei	26
Protocol for 3D screening of lung cancer spheroids using natural products	25
Characterization of allosteric modulators that disrupt androgen receptor co-activator protein-protein interactions to alter transactivation–Drug leads for metastatic castration resistant prostate canc	25
FLECS technology for high-throughput screening of hypercontractile cellular phenotypes in fibrosis: A function-first approach to anti-fibrotic drug discovery	22
Development of a high-throughput TR-FRET screening assay for a fast-cycling KRAS mutant	22
Approaches for Prioritizing High-Quality Chemical Matter in Chemical Probe and Drug Discovery	22
Rapid Compound Integrity Assessment for High-Throughput Screening Hit Triaging	22
Establishing and Validating Cellular Functional Target Engagement Assay for Selective IRAK4 Inhibitor Discovery	22
BRET measurement on CCD camera-based microtiter plate readers	21
Creating a more strategic small molecule biophysical hit characterization workflow	19
Detection and impact of hypoxic regions in multicellular tumor spheroid cultures formed by head and neck squamous cell carcinoma cells lines	19

A Quantitative Bioassay to Determine the Inhibitory Potency of NGF–TrkA Antagonists	18
A Novel High-Throughput FLIPR Tetra–Based Method for Capturing Highly Confluent Kinetic Data for Structure–Kinetic Relationship Guided Early Drug Discovery	18
Screening approaches for the identification of Nrf2-Keap1 protein-protein interaction inhibitors targeting hot spot residues	18
A robust CETSA data analysis automation workflow for routine screening	17
Major Improvements in Robustness and Efficiency during the Screening of Novel Enzyme Effectors by the 3-Point Kinetics Assay	17
SLAS special issue editorial 2022: 3D cell culture approaches of microphysiologically relevant models	16
Reduced levels of serum EPA and DHA identified in patients with non-small-cell lung cancer using a new rapid validated LC-MS/MS method	16
Consideration of vendor-related differences in hepatic metabolic stability data to optimize early ADME screening in drug discovery	16
Identification of chemicals breaking the USP8 interaction with its endocytic substrate CHMP1B	15
POLARISED views and FRETting about probe modulation assays: Learning from High Throughput Screening	15
Multifunctional profiling of triple-negative breast cancer patient-derived tumoroids for disease modeling	15
Screening for positive allosteric modulators of cholecystokinin type 1 receptor potentially useful for management of obesity	15
Optimization of a Colorimetric Assay to Determine Lactate Dehydrogenase B Activity Using Design of Experiments	14
Adipocyte-based high throughput screening for anti-obesity drug discovery: Current status and future perspectives	14
Open-source electrophilic fragment screening platform to identify chemical starting points for UCHL1 covalent inhibitors	13
High throughput application of the NanoBiT Biochemical Assay for the discovery of selective inhibitors of the interaction of PI3K-p110α with KRAS	13
Magnetic 3D bioprinting of skeletal muscle spheroid for a spheroid-based screening assay	13
Merging cultures and disciplines to create a drug discovery ecosystem at Virginia commonwealth university: Medicinal chemistry, structural biology, molecular and behavioral pharmacology and computatio	13
A mechanism of action-reflective, dual cell-based bioassay for determining the bioactivity of sclerostin-neutralizing antibodies	12
Standards for reporting optical biosensor experiments (STROBE): Improving standards in the reporting of optical biosensor-based data in the literature	12
Identification of positive modulators of TRPM5 channel from a high-throughput screen using a fluorescent membrane potential assay	12
Bioassay protocol metadata annotation: Proposed standards adoption	12
Development of a time-resolved fluorescence resonance energy transfer ultra-high throughput screening assay targeting SYK and FCER1G interaction	11
Changing the HTS Paradigm: AI-Driven Iterative Screening for Hit Finding	11
Application of FRET- and BRET-based live-cell biosensors in deorphanization and ligand discovery studies on orphan G protein-coupled receptors	11
Identification of potent small molecule inhibitors of SARS-CoV-2 entry	11
The Problems of Applying Classical Pharmacology Analysis to Modern In Vitro Drug Discovery Assays: Slow Binding Kinetics and High Target Concentration	11
In Vitro three-dimensional (3D) cell culture tools for spheroid and organoid models	11
WITHDRAWN: Detection and impact of hypoxic regions in multicellular tumor spheroid cultures formed by head and neck squamous cell carcinoma cells lines	10
Using chemical and biological data to predict drug toxicity	10
Drug discovery efforts at George Mason University	10
The SLAS Discovery Editor's Top 10 for 2021	9
Nanobodies: A Game-Changer in Cell-Mediated Immunotherapy for Cancer	9
Development of a biotin–streptavidin-enhanced enzyme-linked immunosorbent assay (BA-ELISA) for high-throughput screening of KRASG12C inhibitors	9
A neuronal cell-based reporter system for monitoring the activity of HDAC2	9
Time-resolved FRET screening identifies small molecular modifiers of mutant Huntingtin conformational inflexibility in patient-derived cells	9
Luminescence Energy Transfer–Based Screening and Target Engagement Approaches for Chemical Biology and Drug Discovery	8
Compound management in a virtual research organization: The cornerstone of a reliable MMV discovery engine	8
Development and use of a high-throughput screen to identify novel modulators of the corticotropin releasing factor binding protein	8
Reducing False Positives through the Application of Fluorescence Lifetime Technology: A Comparative Study Using TYK2 Kinase as a Model System	8
A Scalable Approach Reveals Functional Responses of iPSC Cardiomyocyte 3D Spheroids	8
Fragment-based drug discovery of small molecule ligands for the human chemokine CCL28	8
Protocol for kinetic mode potassium channel assays on common plate readers and microscopes	7
Corrigendum to DNA methylation-induced ablation of miR-133a accelerates cancer aggressiveness in glioma through upregulating peroxisome proliferator-activated receptor γ [SLAS Discov. 2022 Sep 5;S2472	7
Hit Discovery Methodology	7
Graph neural networks for the identification of novel inhibitors of a small RNA	7
Covalent hits and where to find them	7
An efficient and scalable data analysis solution for automated electrophysiology platforms	7
Advances in Protein Degradation	7
High-throughput nephelometry methodology for qualitative determination of aqueous solubility of chemical libraries	7

SLAS Discovery – The Next Generation of Research	7
Emerging drug discovery ecosystems	7
Maintaining a High-Quality Screening Collection: The GSK Experience	6
DNA methylation-induced ablation of miR-133a accelerates cancer aggressiveness in glioma through upregulating peroxisome proliferator-activated receptor γ	6
Drug repurposing screen for the rare disease ataxia-telangiectasia	6
Design of experiments for the automated development of a multicellular cardiac model for high-throughput screening	6
High-throughput detection of metal contamination in HTS outputs	6
Assessment of Drug Proarrhythmic Potential in Electrically Paced Human Induced Pluripotent Stem Cell–Derived Ventricular Cardiomyocytes Using Multielectrode Array	6
Real-time thiol detection in iPSC-derived neuron cultures using SemKur-IM, a novel fluorescent dithio probe	6
Absolute quantification of Neuron-specific enolase based on surface plasmon resonance	6
Optimising cell-based bioassays via integrated design of experiments (ixDoE) - A practical guide	6
Novel beta-glucocerebrosidase chaperone compounds identified from cell-based screening reduce pathologically accumulated glucosylsphingosine in iPS-derived neuronal cells	6
Discovery of DTX3L inhibitors through a homogeneous FRET-based assay that monitors formation and removal of poly-ubiquitin chains	6
Replenishing the malaria drug discovery pipeline: Screening and hit evaluation of the MMV Hit Generation Library 1 (HGL1) against asexual blood stage Plasmodium falciparum, using a nano luciferase rep	6
Functional and Pharmacological Comparison of Human and Mouse Na+/Taurocholate Cotransporting Polypeptide (NTCP)	6
HTS driven by fluorescence lifetime detection of FRET identifies activators and inhibitors of cardiac myosin	6